Revolution Medicines (RVMD) holder plans 908-share sale after prior disposals

Rhea-AI Filing Summary

Revolution Medicines shareholder Jeffrey Todd Cislini has filed a notice to sell common stock. The filing covers a planned sale of 908 common shares through Morgan Stanley Smith Barney LLC on or around 01/21/2026 on the NASDAQ market. These shares were acquired as restricted stock units from the issuer on 12/15/2025, and the block has an aggregate market value of $105,527.76.

The notice states that Revolution Medicines had 193,319,805 common shares outstanding at the time referenced. Over the prior three months, Cislini sold 2,688 common shares on 12/16/2025 for $206,483.83 and 13,388 common shares on 11/18/2025 for $939,008.57, with the larger transaction noted as Rule 10b5-1 sales. By signing, the seller represents they are not aware of undisclosed material adverse information about the company’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	908	105527.76	193319805	01/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/15/2025	Restricted Stock Units	Issuer			908	12/15/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JEFFREY TODD CISLINI 700 Saginaw Drive Redwood City CA 94063	Common	12/16/2025	2688	206483.83
10b5-1 Sales for JEFFREY TODD CISLINI 700 Saginaw Drive Redwood City CA 94063	Common	11/18/2025	13388	939008.57

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for RVMD disclose about upcoming share sales?

The filing shows that Jeffrey Todd Cislini plans to sell 908 common shares of Revolution Medicines on or about 01/21/2026 on the NASDAQ, through Morgan Stanley Smith Barney LLC, with an aggregate market value of $105,527.76.

How did the RVMD shares in this Form 144 filing originate?

The 908 common shares to be sold were acquired on 12/15/2025 as restricted stock units from the issuer, with the date of payment also listed as 12/15/2025 and the nature of payment described as N/A.

How many Revolution Medicines shares were outstanding when this Form 144 was prepared?

The Form 144 notes that 193,319,805 common shares of Revolution Medicines were outstanding at the time referenced in the filing.

What RVMD share sales has Jeffrey Todd Cislini made in the past three months?

Over the prior three months, Jeffrey Todd Cislini sold 2,688 common shares on 12/16/2025 for $206,483.83 and 13,388 common shares on 11/18/2025 for $939,008.57, with the latter identified as Rule 10b5-1 sales.

What representation does the seller make in this RVMD Form 144 notice?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about Revolution Medicines’ current or prospective operations that has not been publicly disclosed.

Which broker is handling the planned RVMD share sale in this Form 144?

The planned sale of 908 common shares of Revolution Medicines is listed as being handled by Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.